Sage Therapeutics
$31.759876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$31.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.55 (+1.78%) Today
+$0.25 (+0.79%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!
About SAGE
Sage Therapeutics, Inc. Common Stock, also called Sage Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Read More Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
Employees
675
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
1.57B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.54M
High Today
$32.30
Low Today
$29.43
Open Price
$29.94
Volume
943.66K
52 Week High
$193.56
52 Week Low
$25.01
Collections
Analyst Ratings
67%
of 21 ratings
Buy
67%
Hold
33%
Sell
0%
SAGE Earnings
-$3.61
-$2.41
-$1.20
$0.00
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected Apr 30, Pre-Market